Abstract 1510P
Background
Desmoid fibromatoses are local aggressive mesenchymal tumors with limited treatment options. Due to its toxicity, doxorubicin is generally reserved for rapidly growing and/or life-threatening desmoids. Doxorubicin can be ionically bound to sulfonate -coated hydrogel microbeads, allowing for selective endovascular drug delivery via microbead-loaded doxorubicin eluting embolization. We aimed to evaluate the safety and efficacy of selective intra-arterial doxorubicin-eluting embolization for intra and extra abdominal desmoid fibromatoses.
Methods
This was a combined prospective and retrospective study involving 24 patients treated at six tertiary medical centers. All patients underwent at least one session of selective intra-arterial doxorubicin-eluting embolization therapy. MRI was utilized for imaging follow up. The primary outcome was radiological response as reflected by tumor volume, T2 intensity and RECIST 1.1 criteria. Safety was assessed using the CTCAE grading system.
Results
At a median follow-up interval of 8 months (IQR 3-13), there was a median volume decrease of 59% (IQR 40 -71). T2 MRI signal intensity dropped a median 36% (IQR 19 – 54.8). Using RECIST 1.1 criteria, 9 (39%) patients achieved a partial response, 12 (52%) had stable disease and 2 (9%) had progressive disease. One patient (4%) experienced a grade 3-4 adverse event.
Conclusions
For select patients with desmoid fibromatosis, doxorubicin-eluting therapy is an effective and safe therapeutic option.
Clinical trial identification
NCT03966742.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.